Merck Sharp & Dohme LLC
This trial will help researchers learn if tulisokibart, the trial medicine, can treat non-infectious intermediate, posterior, or panuveitis (NIIPPU) so that steroids can be given for a shorter period of time. In this trial, researchers will look at different doses (amounts) of tulisokibart. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until NIIPPU gets worse. A placebo looks like the trial medicine but has no medicine in it. Using a placebo helps researchers better understand the effects of the trial medicine.
This study consists of a 50-week Double-blind Period and a 134-week Long-term Extension.
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has active noninfectious intermediate uveitis, posterior uveitis, or panuveitis (NIIPPU) at screening and baseline in at least one eye * Meets prior stable dose and duration requirements before baseline for permitted immunosuppressive therapies and corticosteroids Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has isolated anterior uveitis * Has macular edema as the only sign of intermediate, posterior, or panuveitis * Has active ocular disease t…
Subcutaneous (SC) administration
SC administration
Oral administration
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.